Presentation at 18th Annual World Cancer Congress
Coiled Therapeutics plc announced that its Executive Chairman will present on AO-252, a novel TACC3 inhibitor, at the 18th Annual World Cancer Congress on April 16, 2026. The presentation will highlight AO-252's potent activity in multiple solid tumors, including brain metastases, and its potential to address significant unmet needs in oncology. This follows recent clinical trial updates demonstrating superior efficacy and durable responses for AO-252 in heavily pre-treated patients, with the company planning to initiate dose expansion cohorts in lead indications during 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, today announces that its Executive Chairman, Dr. Sotirios G. Stergiopoulos, will be a featured speaker at the 18th Annual World Cancer Congress, taking place in Athens this week on 15 - 17 April 2026 (https://www.bitcongress.com/cancer2026/default.asp).
- Stergiopoulos will deliver a presentation on 16 April 2026, titled: "Novel TACC3 Protein-Protein Interaction Inhibitor, AO-252, A Key Driver in Cancer Functions Such as DDR, Immune Evasion and CIN, Shows Potent Activity in Multiple Solid Tumors Along with Brain Metastasis."
The presentation will highlight the latest findings on the Company's lead candidate, AO-252, a first-in-class TACC3 inhibitor, and its potential to address significant unmet needs in oncology, including the treatment of brain metastases.
This presentation follows the Company's recent clinical trial update which demonstrated a superior efficacy profile and durable clinical responses for AO-252 in a heavily pre-treated patient population.
About AO-252
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.